Navigation Links
CareLex Builds Support for Developing Interoperability Standard for Clinical Trial Data Exchange
Date:9/4/2013

Silicon Valley, California (PRWEB) September 04, 2013

CareLex, a non-profit organization for BioInformatics research, today announced plans to develop an Electronic Trial Master File (eTMF) standard that will modernize traditional paper-based clinical trial data by enabling the use of interoperable information systems. The work, which will build on the recently published eTMF Reference Model for BioPharma, is intended to be advanced as an activity of the OASIS international open standards consortium.

The new eTMF standards initiative will engage global pharmaceutical regulatory agencies, clinical trial sponsors, research organizations, consultants, industry groups and others in the BioPharma industry. These organizations will collaborate to evaluate current technologies, identify content classification models, and define an open, internationally recognized standard that will assure information interoperability among clinical trial stakeholders.

"We are excited to see increased interest and adoption of eTMF systems in clinical trials; however, without an open, standards-based eTMF content model, document and record sharing will continue to be inefficient and subject to human data entry errors," said Zachariah Schmidt, Executive Director and Founder of CareLex. "There is an urgent need for a globally available, open eTMF standard that will accelerate automated information exchange and interoperability, and that will facilitate regulatory agency compliance. The eTMF standard is essential for ensuring delivery of safe therapies to patients."

Schmidt is gathering support from key healthcare organizations, government agencies, and industry experts and expects to convene an eTMF Technical Committee at OASIS in the coming weeks.

"At OASIS, we are committed to coordinating our efforts with BioPharma stakeholders and regulatory agencies worldwide to advance the development of specifications that leverage interoperable standards for the clinical trials area," said Laurent Liscia, executive director and CEO of OASIS. "We look forward to advancing the eTMF work."

Individuals with demonstrated expertise in domain areas related to clinical trial content classification, regulatory compliance, content management or software information modeling are invited to take a leadership role in the eTMF standardization initiative. Participation will be open to all interested parties. Details are available by contacting Zack Schmidt via the CareLex website at http://www.CareLex.org or email at admin(at)CareLex(dot)org, OASIS, or email at join(at)oasis-open(dot)org. Join the new LinkedIn eTMF Standards discussion group at http://www.linkedin.com/groups/eTMF-Standards-5161997/about.

About CareLex

CareLex™ is a non-profit public benefit organization for BioInformatics research and development. Organized in 2012 by a core group of clinical trial domain and bioinformatics experts, CareLex provides open source technology for BioPharma content classification and management. CareLex is open to anyone worldwide. For more information, visit http://www.CareLex.org/.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11088154.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. UK nanodevice builds electricity from tiny pieces
2. Rice builds nanotube photodetector
3. Core Facility Management Software Company Builds API to Extend Complex Workflows in Research
4. Synteract and MediciNova Partner in "Fight For Air Walk" to Support the American Lung Association in California
5. inVentiv Health Selected to Provide Sales Operations Support for Santarus
6. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
7. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
8. ERT Launches New Website to Support Significant Commercial Growth
9. NSF CAREER grants support ocean energy, microforming, computer planning
10. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
11. Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... and multilingual testing services, announced today the launch of its revamped and improved ... of scalable language service solutions, the redesigned website will better communicate how the ...
(Date:2/9/2016)... NJ (PRWEB) , ... February 09, 2016 , ... ... Dorman, former Vice President for Public Policy for the National Organization for Rare ... patient advocacy groups to ensure their voices are heard throughout the drug regulatory ...
(Date:2/9/2016)... 2016 BERG, a biopharmaceutical company uncovering ... has announced the appointment of Jason Haddock ... Officer. Haddock brings to BERG over 20 years ... in senior financial functions at pharmaceutical companies, as ... management. Niven R. Narain , ...
(Date:2/8/2016)... 8, 2016 --> ... an innovation-driven oncology company developing next generation cancer ... today announced that chairman emeritus of Tata Sons ... the company as part of the first close ... investors Navam Capital and Aarin Capital. ...
Breaking Biology Technology:
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
Breaking Biology News(10 mins):